Version 1.0.3

Submission
Home > Submission

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/10/2014
Deadline Date	30/10/2014
Date Submitted	29/10/2014
Туре	Historic Performance in Initiating
NHS provider	Maidstone and Tunbridge Wells NHS Trust

Showing records 1 to 13 of 13. Pages: 1

System generated field. Please check your dates if value is negative.

12441	12440	12439	42438	d
42441 13/SC/0323	42440 13/NW/0612	42439 09/MRE00/53	42438 11/WS/0039	Research Ethics Committee Committee Reference Number
77.7	71.7			Integrated Research Application System Number
NHS Permission	NHS Permission	NHS Permission	NHS Permission	Submission Type
PHOENIX - A randomised, Double-blind, Double-blind, Placebo-controlled Phase 3 study of the Bruton's Tyrosine Kinases (BTK) Inhibitor, PCI-32765 (brutinib), in combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone	Benralizumab treatment in patients with unconrolled asthma (SIROCCO)	BR14 Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial	I/lia trial of AZD4547 in combination with Cispletin and Capecitabine (CX)	
14/04/2014 29/04/2014 Yes	28/02/2014 09/04/2014 No	06/05/2014	19/05/2014	Date of Receipt of Valid Research Application
29/04/2014	09/04/2014	12/05/2014 No	19/05/2014 21/05/2014 No	Date of First NHS Patient Permission Recruited?
	No	N _o	N _o	First Patient Recruited?
04/06/2014 15	40	o	N	Date of the First Patient Recruited F
	0	-		Duration between VRA and NHS Permission
				Duration Duration between between VRA NHS Permission and and First First Patient Patient
51				ation /een
				ation /een /Site cted Date
				Duration Duration between between Date Site Date Site Confirmed Selected and First Patient Patient Patient Recruited Recruited
				<u> </u>
Yes	No	N _o	2 0	Benchmark Met
				Date Site Invited
				Date Date HRA Site Site Appu Invited Selected Date
				oval
				Date Site Confirmed Date Site By Confirme Sponsor
(O T)	(0 T)	(0.7)	(0.T)	Ω.
Please Select	Please Select	Please Select	Please Select	Non- Confirm Status

42442 13/EM/0230

NHS Permission

Within 70 Days

Please Select..

Placebo-Controlled, Multicentre Study of VS 6063 in Multicentre
evaluation of the
Aquesys Xen
implant in moderate
primary open angle
glaucoma subjects Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Carboplatin and Paclitaxel in Comparing Veliparib Plus Carboplatin and Paclitaxel Versus (R_CHOP) in subjects phase II Randimised, Double Blind, pragmatic randomised controlled open trial of the effect of SWIFFT: Scaphoid
Waist Internal
Fixation for
Fractures Trial preventing dark adaptation in the treatment of early diabetic macular supplementation to enteral Lactoferrin centre randomised placebo-controlled ELFIN: A multi-Phase 3 Study Malignant Pleurel Mesothelioma. Subjects with COMMAND: A to test the clinical eficacy of trial of prophylactic Placebo Plus AbbVie M11-089 -CLEOPATRA: A invasive infection in prevent late-onset controlled single masked clinical trial III randomised multicentre phase very preterm TITRATE - A Post Market ightMasks at 01/08/2014 22/07/2014 06/08/2014 17/04/2014 23/05/2014 09/04/2014 27/03/2014 14/08/2014 03/06/2014 09/07/2014 17/04/2014 23/05/2014 No N_O N_o Yes - Date Unavailable Yes Yes CTP Submission Platform - Submission (Version 1.0.3) 01/09/2014 55 23/05/2014 21 83 13 15 36 90 57 145

N_O

Please Select...

42444 13/EM/0118

NHS Permission

42445 13/LO/0145

NHS Permission

No

Please Select..

No

Please Select..

Yes

Please Select...

42443 14/SW/0091

SHN

Within 70 Days

Please Select...

Permission

Previously

Jntreated

SHN

management (IM)

42447 13/EM/0154

NHS Permission

42446 14/EE/005

SHN Permission

Please

Within 70

CTP Submission Platform - Submission (Version 1.0.3)

42450 1	42449 4	42448 1
42450 13/EM/0459	42449 43/EM/0415	42448 13/LO/1308
159	115	8
NHS	NHS Permission	Permi
		Permission compared with standard care (on re mission rat 12 months in Rheumatoid Arthritis patient with intermedial
POSNOC - Positive Sentinel Positive Sentinel Node: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy. A randomised controlled trail of axillary treatment women with early stage breast can who have metastases in on or two sentiel	EPOCH Trial: Enhanced Per Operative Carr high-risk patier (EPOCH) Trial	compared with standard care (St on re mission rate at 12 months in Rheumatoid Arthritis patients with intermediate
POSNOC - Positive Sentinel Node: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy. A randomised controlled trail of axillary treatment in women with early stage breast cancer who have metastases in one	EPOCH Trial: Enhanced Peri- Operative Care for high-risk patients (EPOCH) Trial	compared with standard care (SC) on re mission rates at 12 months in Rheumatoid Arthritis patients with intermediate with intermediate
	r 06/03	107
/2014	V2014	W2014
23/07/2014 06/08/2014 No	06/03/2014 08/04/2014 No	12/08/2014 27/08/2014 No
14 No	14 No	14 No
74	33	
		 ,
Within 70 Days	N _o	Days
70		
Please Select	Please Select	Select
F •	: °	f

Copyright (c) Exbos Limited 2013. All Rights Reserved. Web site developed in the City of Leeds, England by Exbos Limited the bespoke software specialists.



http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionId=26&SubmissionId=922&TrustId=1119

